Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Average Recommendation of “Buy” from Brokerages

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) has earned a consensus rating of “Buy” from the nine brokerages that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation, seven have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $35.71.

Several equities research analysts have recently commented on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $33.00 target price on shares of Day One Biopharmaceuticals in a research report on Thursday, October 31st. HC Wainwright restated a “buy” rating and issued a $40.00 price objective on shares of Day One Biopharmaceuticals in a report on Thursday, October 31st. Finally, TD Cowen raised Day One Biopharmaceuticals to a “strong-buy” rating in a research report on Monday, November 4th.

Insider Buying and Selling

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 30,000 shares of the business’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $13.31, for a total value of $399,300.00. Following the sale, the insider now directly owns 1,034,015 shares of the company’s stock, valued at approximately $13,762,739.65. The trade was a 2.82 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders have sold 51,745 shares of company stock valued at $748,567 over the last quarter. Corporate insiders own 8.40% of the company’s stock.

Hedge Funds Weigh In On Day One Biopharmaceuticals

Several large investors have recently modified their holdings of DAWN. First Turn Management LLC purchased a new stake in Day One Biopharmaceuticals during the 3rd quarter valued at about $13,204,000. GSA Capital Partners LLP bought a new position in shares of Day One Biopharmaceuticals in the third quarter worth approximately $825,000. Algert Global LLC lifted its stake in shares of Day One Biopharmaceuticals by 248.8% in the third quarter. Algert Global LLC now owns 71,487 shares of the company’s stock worth $996,000 after buying an additional 50,990 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Day One Biopharmaceuticals by 14.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 507,448 shares of the company’s stock valued at $7,069,000 after buying an additional 64,700 shares during the last quarter. Finally, Vestal Point Capital LP increased its position in shares of Day One Biopharmaceuticals by 100.0% during the third quarter. Vestal Point Capital LP now owns 2,500,000 shares of the company’s stock valued at $34,825,000 after acquiring an additional 1,250,000 shares in the last quarter. Hedge funds and other institutional investors own 87.95% of the company’s stock.

Day One Biopharmaceuticals Price Performance

DAWN opened at $12.79 on Monday. The firm has a market capitalization of $1.29 billion, a price-to-earnings ratio of -12.42 and a beta of -1.51. Day One Biopharmaceuticals has a one year low of $11.94 and a one year high of $18.07. The business has a 50 day simple moving average of $14.07 and a two-hundred day simple moving average of $14.02.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its earnings results on Wednesday, October 30th. The company reported $0.38 EPS for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.58. The business had revenue of $93.76 million for the quarter, compared to the consensus estimate of $15.05 million. During the same quarter in the prior year, the company earned ($0.54) EPS. As a group, sell-side analysts expect that Day One Biopharmaceuticals will post -0.88 EPS for the current fiscal year.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.